Iris Acquisition Corp II (IRAB) Company Overview

What does Iris Acquisition Corp II do?

Iris Acquisition Corp II is not an operating company with products, customers, factories, or recurring revenue. It is a Cayman Islands special purpose acquisition company, or SPAC, created to raise cash in a public offering and then combine with a private business. The official 2025 Form 10-K describes a globally focused, generalist search for a small- to mid-market company that could benefit from public-market access, transaction expertise, and growth capital.

Legal identity and listed securities

Incorporated on July 8, 2025, Iris is listed on the New York Stock Exchange. Its units trade as IRABU, Class A shares as IRAB, and warrants as IRABW. Each public unit contained one Class A share and one-half warrant; each whole warrant has an $11.50 exercise price. Separate trading began February 24, 2026.

What the company is—and is not

Iris packages protected acquisition capital, listed securities, and a sponsor team that searches for a deal. It does not yet own the business that would generate sales or free cash flow. Analysis therefore starts with governance, trust protection, sponsor incentives, target quality, redemptions, and dilution—not a conventional operating-company DCF.

How does Iris Acquisition Corp II make money before a deal?

Before a combination, Iris has no customer revenue. Income comes mainly from trust-account interest, while public-company and transaction-search costs run through expenses. In Q1 2026, $919,562 of trust interest exceeded $144,112 of general and administrative costs and $1,515 of loan interest, producing $773,935 of net income. This is incidental income, not an operating moat.

Three economic constituencies

Public shareholders own redeemable Class A shares and may retain warrants; their principal pre-deal anchor is the per-share trust amount. The sponsor owns founder shares and private units, creating upside if a transaction closes and loss exposure if Iris liquidates. A target’s owners focus on valuation, post-redemption cash, governance, and public-market credibility.

What kind of target is Iris seeking?

The final IPO prospectus lists technology, media and telecommunications; business and IT services; consumer and digital brands; hospitality and real-estate platforms; education technology; logistics and mobility; automotive and industrial technology; and fintech or crypto among areas of interest. The mandate remains flexible. Management emphasizes established operating history, recurring or predictable revenue, positive or near-positive cash flow, technology-enabled margin improvement, defensible positioning, and a credible post-transaction growth plan.

What does the latest reported period show?

The latest full financial package is the Form 10-Q for the quarter ended March 31, 2026. It captures the IPO close, the creation of the trust account, the first period of trust interest, and the accounting effect of redeemable shares. The company reported no operating revenue because a business combination had not occurred.

What changed in the first quarter?

Why does the balance-sheet presentation look unusual?

The 16.85 million public Class A shares are classified outside permanent equity because holders can redeem them. At March 31, 2026, the redemption liability-like temporary-equity amount was $169.42 million. Iris also reported $7.43 million of total liabilities, including a $7.115 million deferred underwriting fee, and a $6.44 million shareholders’ deficit. That deficit does not mean the trust disappeared; it reflects SPAC accounting, including the accretion of redeemable shares to their redemption amount.

Trust capital, redemptions, and sponsor economics define the model

A SPAC’s central asset is its trust account. Iris deposited $168.5 million after the February 4, 2026 IPO, or $10.00 per public unit. By March 31, trust cash was $169.42 million, approximately $10.05 per redeemable public share. The trust is generally reserved for a combination, redemptions, taxes, and limited dissolution expenses.

How protected is the capital pool?

Trust protection differs from ordinary operating-company risk, but it does not guarantee post-deal value. Holders may redeem before a combination; those who remain accept the target’s economics, financing terms, and dilution. Iris has 24 months from the IPO closing to complete a deal unless the deadline is amended. Otherwise, public shares are generally redeemed and warrants expire worthless.

Where does dilution enter?

Founder shares are the main structural dilution layer. The sponsor bought 5.75 million Class B shares for $25,000 in July 2025; 133,333 were later forfeited, leaving 5.616667 million. Public units created 8.425 million warrants, and 438,000 private units added 219,000. A deal may also add PIPE shares, seller equity, debt, earnouts, or incentives. Enterprise value must therefore be converted to fully diluted equity value.

Which turning points shape Iris today?

The brief history is strategically dense. Each event altered capital, sponsor incentives, trading structure, or the target narrative. The timeline below focuses on decisions that still matter to investors rather than corporate trivia.

1. Jul. 8, 2025
   Iris Acquisition Corp II was incorporated in the Cayman Islands, beginning the organizational phase.
2. Jul. 15, 2025
   The sponsor acquired 5.75 million founder shares for $25,000, establishing the promote economics.
3. Feb. 2, 2026
   The IPO was priced at 15 million units at $10.00; governance, warrant, trust, and private-placement agreements became operative.
4. Feb. 4, 2026
   The IPO closed at 16.85 million units after a partial over-allotment exercise, generating $168.5 million of public proceeds.
5. Feb. 24, 2026
   Class A shares and warrants became separately tradable, creating distinct redemption and optionality instruments.
6. Mar. 9, 2026
   Iris announced a non-binding letter of intent with Freedom Metals Corporation, briefly introducing a critical-minerals thesis.
7. Mar. 30, 2026
   The administrative-services arrangement was amended while retaining a $20,000 monthly office and support fee.
8. May 13, 2026
   Iris terminated the Freedom Metals letter of intent, returning the company to an uncommitted target-search position.

The March-to-May sequence is analytically important. The Freedom Metals announcement showed that management could move quickly from IPO to a potential target, but the subsequent May 13, 2026 Form 8-K demonstrates that a non-binding LOI is not equivalent to a signed merger agreement. For researchers, the lesson is to assign value only after transaction terms, audited target financials, financing commitments, and redemption mechanics are disclosed.

What gives Iris a competitive position in the SPAC market?

Iris competes with other SPACs, private-equity funds, strategic acquirers, growth investors, and traditional IPOs. The prospectus warns that many rivals have greater technical, human, financial, or local-industry resources. Iris has no conventional moat; its narrower advantages are sponsor relationships, cross-border experience, a ready NYSE vehicle, and sector flexibility.

Where can the sponsor add differentiated value?

Management’s public materials emphasize experience across private equity, investment banking, real estate, digital platforms, technology, and cross-border deals in North America, the Middle East, Asia, and Europe. The team also cites the predecessor Iris Acquisition Corp transaction with Liminatus Pharma. The official investor-relations overview presents that network as the platform’s primary strategic asset.

Why is the advantage still unproven?

Network access matters only if it produces a defensible target at a financeable valuation. The market will judge revenue quality, cash conversion, management, controls, and deal terms—not pre-deal trust interest.

Who owns IRAB and why does control matter?

Ownership matters because founder shares, board influence, and transaction incentives shape the pre-deal process. As of March 26, 2026, Iris Acquisition Holdings II LLC beneficially owned 251,000 Class A shares and all 5.616667 million Class B shares: 5.867667 million ordinary shares, or about 25.62% of the total. Sumit Mehta and Rohit Nanani each own 50% of the sponsor’s managing member.

How concentrated is sponsor control?

The official sponsor Schedule 13G confirms shared voting and dispositive influence over the sponsor position. Separate filings disclose the Adage position and the Aristeia position.

What governance signals should researchers read?

The board includes a chairman, the CEO-director, and independent directors on audit, compensation, and governance committees. Founder shares carry pre-combination rights, including director appointment or removal under the governing documents. Sponsor administrative fees are $20,000 per month. These disclosed arrangements still require investors to separate target economics from sponsor incentives.

What risks could change the outcome?

Iris’s risk profile is dominated by transaction uncertainty, not product demand. It must identify a target, complete diligence, secure financing, satisfy regulators and the NYSE, obtain required approvals, and retain enough cash after redemptions. The terminated Freedom Metals LOI shows that an announced opportunity can disappear before definitive documentation.

Which execution risks are most material?

What less obvious constraints matter?

The prospectus notes intense target competition and fewer resources than larger buyers. Iris relies heavily on third-party technology and had no formal cybersecurity risk-management program as of the 2025 Form 10-K. Cayman incorporation also affects shareholder-rights analysis. A future target may introduce weak controls, complex accounting, regulation, or capital needs not visible while Iris remains a shell.

Risk analysis remains conditional. Iris itself has no product concentration, commodity cycle, patent cliff, or churn metric. Those risks arrive with a target. For now, search quality, timing, incentives, capital retention, and deal structure dominate.

Which KPIs and valuation drivers matter most?

A pre-deal SPAC needs a different dashboard. Revenue, gross margin, and EBITDA become useful only after a target provides audited results. Until then, monitor trust value per share, outside-trust liquidity, search costs, time remaining, redemption exposure, sponsor and warrant dilution, and negotiation status.

What should researchers monitor now?

Why is a conventional DCF premature?

A DCF discounts operating free cash flow. Iris has no operating revenue, customer-derived margin, or target forecast. Discounting trust interest would value a temporary cash pool, not a post-combination enterprise. A disciplined pre-deal framework separates trust value, warrant optionality, and a probability-weighted transaction surplus or deficit after dilution and costs.

After a target is announced, DCF sensitivities become target-specific: growth, margins, cash conversion, capital intensity, financing, terminal growth, and discount rate. Redemption cash, fees, warrants, and sponsor dilution then modify equity value. Before those inputs exist, numerical precision is false precision.

What is the key takeaway from Iris Acquisition Corp II?

Iris Acquisition Corp II is best understood as a listed acquisition mandate backed by approximately $169.42 million of trust cash at March 31, 2026—not as a conventional operating company. Its current financial strength comes from protected liquidity and low near-term operating cash use, while its strategic value depends on the sponsor’s ability to source, price, finance, and close a high-quality transaction.

The strongest support for the story is the clear trust structure, the $10.05 redemption value per public share at March 31, 2026, a sponsor team with prior SPAC and cross-border transaction experience, and a broad target mandate. The main counterweights are equally clear: no current operating business, a terminated first LOI, a 24-month clock, intense competition for targets, sponsor-led control, and meaningful dilution from 5.616667 million founder shares plus warrants.

The practical watchlist is therefore compact: a new target announcement, a signed merger agreement, the target’s audited statements, the proposed enterprise value, minimum-cash conditions, redemption levels, PIPE or debt commitments, fully diluted share count, and the combined company’s free-cash-flow potential. Those disclosures will determine whether Iris evolves from a capital pool into a durable public company or returns capital through liquidation.